Document Detail


Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR.
MedLine Citation:
PMID:  21086246     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVE: To assess the efficacy of different dosing intervals of lanreotide, Somatuline Autogel (®) (Lan-ATG) 120 mg in patients with acromegaly, previously treated with octreotide, long-acting release (Oct-LAR).
PATIENTS AND STUDY DESIGN: Patients previously on Oct-LAR 10, 20, or 30 mg were switched to 6 repeated deep subcutaneous injections of Lan-ATG 120 mg at intervals of 56, 42, or 28 days, respectively. After the third injection, dose intervals were adjusted on the basis of insulin-like growth factor 1 (IGF-1) levels.
RESULTS: The ITT (Intention To Treat) population comprised 35 patients who received at least one dose of study medication and at least one post-baseline efficacy assessment. Overall, 62.9% (n=22) of patients had normalised IGF-1 levels with Lan-ATG at study end (one injection interval after the 6 (th) injection of Lan-ATG), which was similar to the proportion at baseline (60.0% [n=21]). QoL did not change from baseline to study end. Patient preference for Lan-ATG was highest in the 56-day dosing interval group: 71%, 54% and 41% of the patients in the 56, 42 and 28 day groups, respectively, expressed a preference for treatment with Lan-ATG (preference for Oct-LAR: 29%, 9% and 35%, respectively, while the remainder had no preference).
CONCLUSION: Lan-ATG 120 mg injected at intervals of 56, 42 and 28 days provided equivalent hormonal control and QoL to Oct-LAR 10, 20 and 30 mg injected every 28 days, respectively. The proportion of patients preferring Lan-ATG treatment was greater in the longer injection interval groups.
Authors:
J Schopohl; C J Strasburger; D Caird; K Badenhoop; F Beuschlein; M Droste; U Plöckinger; S Petersenn
Related Documents :
6625216 - Inotropic and anesthetic potencies of etomidate and thiopental in dogs.
23038006 - Postnatal exposure to low-dose decabromodiphenyl ether adversely affects mouse testes b...
7528296 - Pharmacologic and pharmacodynamic effects of the selective low km cyclic amp phosphodie...
9038946 - No modulates autonomic effects on sinus discharge rate and av nodal conduction in open-...
6625216 - Inotropic and anesthetic potencies of etomidate and thiopental in dogs.
19460516 - A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prev...
Publication Detail:
Type:  Journal Article     Date:  2010-11-17
Journal Detail:
Title:  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association     Volume:  119     ISSN:  1439-3646     ISO Abbreviation:  Exp. Clin. Endocrinol. Diabetes     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505926     Medline TA:  Exp Clin Endocrinol Diabetes     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  156-62     Citation Subset:  IM    
Copyright Information:
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.
Affiliation:
Medizinische Klinik Innenstadt, Ludwig-Maximilians University, Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Do clown visits improve psychological and sense of physical well-being of hospitalized pediatric pat...
Next Document:  Relationship between thyrotropin and body mass index in euthyroid subjects.